These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8831190)
1. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media]. Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria]. Kawahara S; Tada A; Nagare H Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326 [TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media]. Tomioka H; Sato K; Saito H Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881 [TBL] [Abstract][Full Text] [Related]
4. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis]. Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726 [TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351 [TBL] [Abstract][Full Text] [Related]
6. [Antimycobacterial activities of a new quinolone, sparfloxacin]. Tomioka H; Sato K; Saito H Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089 [TBL] [Abstract][Full Text] [Related]
7. Determination of the susceptibility in vitro of 54 isolates of Mycobacterium fortuitum against three fluoroquinolones using two methods. Hernández AM; Arias A; Felipe A; Alvarez R; Sierra A J Chemother; 1995 Apr; 7(2):109-13. PubMed ID: 7666115 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic potential of sparfloxacin for preventing mycobacterial infections]. Kawahara S; Tada A; Takeuchi M; Kamisaka K; Okada C; Mishima Y; Soda R; Takahashi K; Kibata M; Nagare H Kekkaku; 1994 May; 69(5):351-6. PubMed ID: 8007520 [TBL] [Abstract][Full Text] [Related]
9. [In vitro antimycobacterial activity of a new quinolone, NM394]. Tomioka H; Sato K; Saito H Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Rastogi N; Goh KS Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872 [TBL] [Abstract][Full Text] [Related]
11. [In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis]. Fukuyama M; Kawakami K; Suda O; Imagawa Y Kansenshogaku Zasshi; 1995 Sep; 69(9):987-90. PubMed ID: 7594800 [TBL] [Abstract][Full Text] [Related]
12. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Tomioka H; Saito H; Sato K Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738 [TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis. Karak K; De PK Indian J Med Res; 1995 Apr; 101():147-9. PubMed ID: 7751043 [TBL] [Abstract][Full Text] [Related]
15. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium]. Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866 [TBL] [Abstract][Full Text] [Related]
16. [In vitro antimycobacterial activity of a new quinolone, T-3761]. Tomioka H; Sato K; Saito H Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982 [TBL] [Abstract][Full Text] [Related]
17. [In vitro antimycobacterial activities of a new quinolone, balofloxacin]. Kawahara S; Tada A; Nagare H Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780 [TBL] [Abstract][Full Text] [Related]
18. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media. Kamala T; Herbert D; Venkatesan P; Paramasivan CN Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493 [TBL] [Abstract][Full Text] [Related]
19. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195 [TBL] [Abstract][Full Text] [Related]
20. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Bhusal Y; Shiohira CM; Yamane N Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]